Archive for Daily News

BPC May 24 updates: CTIX release Phase 2 data + XBIT

May 24, 2016 No Comments by

Updates to the Company Pipeline Database for May 24, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary CTIX 1.59 Cellceutix Placque psoriasis Phase 2 Phase 2 top line data released May 2016 XBIT 2.44 Xilonix Colorectal cancer Phase 3 Phase 3 prelim data to be presented July 2 2016 […]

Daily News Read more

BPC May 23 updates: EXEL release Phase 2 RCC data + NVCR VTL trial updates

May 23, 2016 No Comments by

Updates to the Company Pipeline Database for May 23, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary EXEL 6.00 Cabozantinib – CABOSUN Cancer – First-Line RCC Phase 2 Phase 2 data released May 2016 – enpoint met NVCR 11.52 Tumor Treating Fields (TTFields) – PANOVA Pancreatic cancer Phase 2 […]

Daily News Read more

BPC May 19 updates – PTIE DRRX Advisory Committee Meeting set for August 5 + updates for AGIO ASND GBT IMMU INFI ONCE QURE STML TENX TNXP

May 19, 2016 No Comments by

Updates to the Company Pipeline Database for May 19, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary AGIO 45.30 AG-348 Pyruvate kinase deficiency Phase 2 Phase 2 first data due at European Hematology Association (EHA) in June 11 2016 ASND 14.03 TransCon Growth hormone deficiency in children Phase 2 Phase […]

Daily News Read more

BPC May 18 updates – ARIA and DNAI Phase 2 data due at ASCO + updates for AFMD ARRY IMGN ORMP

May 18, 2016 No Comments

Updates to the Company Pipeline Database for May 18, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary AFMD 3.10 AFM13 Hodgkin Lymphoma Phase 2 Phase 2a enrolment has slowed. Company to provide timeline update once enrolment trend is established ARIA 7.85 Brigatinib – ALTA trial Anaplastic lymphoma kinase positive (ALK+) […]

Read more

BPC May 17 updates – PTN Phase 3 data due 3Q + updates for BLRX CFRX NAVB

May 17, 2016 No Comments

Updates to the Company Pipeline Database for May 17, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary BLRX 0.96 BL-8040 Mobilization and collection of bone marrow stem cells Phase 2 Phase 2 trial initiated March 2016. Partial data due by end of 2016 with topline data due by the end […]

Read more

BPC May 16 updates – TRVN and ADRO miss endpoints in Phase 2b trails + updates from ADHD AIMT CERC CLSN CRBP DPRX MCRB PSTI SPHS SYN

May 16, 2016 2 Comments

Updates to the Company Pipeline Database for May 16, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary ADHD 4.17 MDX (Metadoxine Extended Release (MG01CI)) Adult ADHD Phase 3 Data from second Phase 3 trial due by end of 2016 ADHD 4.17 MDX (Metadoxine Extended Release (MG01CI)) Pediatric ADHD Phase 2b […]

Read more

BPC Databse updates for May 12 – Reporting companies CAPR CATB CDTX DPRX GBIM GBT GNVC HSGX IMUC KTOV MIRN NEOT OGXI OPXA REPH RXII VTVT ZSAN

May 12, 2016 No Comments

Updates to the Company Pipeline Database for May 12, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts: CAPR 3.58 CAP-1002 HOPE-Duchenne Duchenne Muscular Dystrophy (DMD) Phase 1/2 Phase 1/2 data due 1Q 2017 CAPR 3.58 CAP-1002 ALLSTAR Myocardial infarction (heart attack) Phase 2 Phase 2 enrolling. 6 month data due 1Q 2017 CATB 4.45 CAT-1004 Duchenne […]

Read more

BPC database updates for May 11 – CYTR Phase 3 data due end of June. CTIX Phase 2 data due this month + updates from reporting companies ABIO ACRS AUPH AVXL CBAY CRMD CYCC EARS ITEK LIFE ONTX TCON

May 11, 2016 No Comments

Updates to the Company Pipeline Database for May 11, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary ABIO 3.23 Gencaro – GENETIC-AF trial Chronic Heart Failure Phase 2b Phase 2b interim analysis due 2Q 2017 ACRS 17.97 A-101 Seborrheic keratosis (SK) Phase 3 Phase 3 data due 3Q 2016 ACRS […]

Read more

Pipeline updates from reporting companies – ARIA AVEO BCLI BDSI BLPH BSTC BTX CCXI CERU CYTX DERM FOMX GALE GTXI IMDZ MDGN OCUL OMER PBYI STEM TGTX TKAI VICL VKTX VTAE XENE ZIOP

May 11, 2016 No Comments

Updates to the Company Pipeline Database for May 10, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary ARIA 7.64 AP32788 Cancer – non-small cell lung cancer (NSCLC) Phase 1/2 Phase 1/2 enrolling as of May 2016 ARIA 7.64 Brigatinib – ALTA trial Anaplastic lymphoma kinase positive (ALK+) metastatic non-small cell […]

Read more

NLNK plunges on poor Phase 3 data + updates from reporting companies AEZS ANTH ARDX CHRS CUR EPZM FATE FGEN FOMX HALO IDRA INO KITE KPTI LBIO OPK OTIC PFNX PLX PRTO RARE RNN TBPH TBRA TNXP VTL CMRX RVNC LJPC MSTX

May 10, 2016 No Comments

Updates to the Company Pipeline Database for May 9, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary AEZS 3.48 Macimorelin Acetate – Macrilen Adult Growth Deficiency Phase 3 CRL Nov 5 2014. Initiated Phase 3 trial in November 2015, to be completed 3Q 2016 AEZS 3.48 Zoptrex Cancer – […]

Read more

KMPH crashes by over half following Advisory Committee meeting + 60 updates from reporting companies

May 06, 2016 No Comments

Updates to the Company Pipeline Database for May 5, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary AERI 14.52 Roclatan – Mercury trials Glaucoma Phase 3 Phase 3 Mercury 1 data due 3Q 2016. Mercury 2 trial data due 2Q 2017 AGIO 43.15 AG-348 Pyruvate kinase deficiency Phase 2 […]

Read more